Skip to main content
SpringerLink
Log in

Alemtuzumab

Paradoxical multiple sclerosis: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Rabaneda-Lombarte N, et al. Tumefactive demyelinating lesions in multiple sclerosis 24 months after the 2nd cycle of alemtuzumab: changes in immune cell populations and candidate biomarkers. Multiple Sclerosis Journal 28 (Suppl.): 848-849 (plus poster), No. 3, Oct 2022. Available from: URL: http://doi.org/10.1177/13524585221123682 [abstract]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alemtuzumab. Reactions Weekly 1936, 23 (2022). https://doi.org/10.1007/s40278-022-29220-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-29220-2

Search

Navigation